Association of diabetes and diabetes treatment with incidence of breast cancer

Acta Diabetologica

Volumn 53, Issue 1, 2016, Pages 99-107

  García Esquinas, Esther ^a,b,c,d   Guinó, Elisabeth ^d,e   Castaño Vinyals, Gemma ^d,f,g,h   Pérez Gómez, Beatriz ^a,d,i   Llorca, Javier ^d,j   Altzibar, Jone M ^d,k   Peiró Pérez, Rosana ^d,l   Martín, Vicente ^d,m   Moreno Iribas, Concepción ^n,o   Tardón, Adonina ^d,p   Caballero, Francisco Javier ^q,r   Puig Vives, Montse ^s   Guevara, Marcela ^d,n   Villa, Tania Fernández ^m   Salas, Dolores ^d,l   Amiano, Pilar ^d,k   Dierssen Sotos, Trinidad ^d,j   Pastor Barriuso, Roberto ^a,d,i   Sala, María ^g   Kogevinas, Manolis ^d,f,g,h,u   Aragonés, Nuria ^a,d,i   Moreno, Víctor ^d,e,t   Pollán, Marina ^a,d,i   more..

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h UNIVERSITAT POMPEU FABRA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j UNIVERSITY OF CANTABRIA   (Spain)

^k BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^l AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^m UNIVERSITY OF LEÓN   (Spain)

ⁿ INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^o Navarrabiomed Fundación Miguel Servet Red de Investigación en Servicios de Salud en Enfermedades Crónicas REDISSEC   (Spain)

^p UNIVERSITY OF OVIEDO   (Spain)

^q HOSPITAL INFANTA ELENA   (Spain)

^r UNIVERSITY OF HUELVA   (Spain)

^s GENERALITAT DE CATALUNYA   (Spain)

^t UNIVERSITY OF BARCELONA   (Spain)

^u School of Public Health   (Greece)

more..

Author keywords

Breast cancer; Diabetes Mellitus; Insulin; Metformin; Triple negative breast neoplasms

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK REDUCTION; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; CASE CONTROL STUDY; COMPLICATION; INCIDENCE; MIDDLE AGED; SPAIN;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; INCIDENCE; METFORMIN; MIDDLE AGED; POSTMENOPAUSE; SPAIN;

EID: 84957949461     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-015-0756-6     Document Type: Article

References (37)

1. IDF (2013) Diabetes Atlas. 5th Edition. Brussels: International Diabetes Federation, 2012. http://www.idf.org/diabetesatlas/5e/europe
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403
3. Shikata K, Ninomiya T, Kiyohara Y (2013) Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci 104(1):9–14
4. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373(9682):2215–2221
5. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG (2012) Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55(6):1607–1618
6. Renehan A, Smith U, Kirkman MS (2010) Linking diabetes and cancer: a consensus on complexity. Lancet 375(9733):2201–2202
7. Reeves KW, McLaughlin V, Fredman L, Ensrud K, Cauley JA (2012) Components of metabolic syndrome and risk of breast cancer by prognostic features in the study of osteoporotic fractures cohort. Cancer Causes Control 23(8):1241–1251
8. Bowker SL, Richardson K, Marra CA, Johnson JA (2011) Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women. Diabetes Care 34(12):2542–2544
9. Carstensen B, Witte DR, Friis S (2012) Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 55(4):948–958
10. Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T et al (2012) Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 30(23):2844–2852
11. Davis AA, Kaklamani VG (2012) Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer 2012:809291
12. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139
13. Maiti B, Kundranda MN, Spiro TP, Daw HA (2010) The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat 121(2):479–483
14. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R et al (1992) Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52(14):3924–3930
15. Parisot JP, Hu XF, DeLuise M, Zalcberg JR (1999) Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer 79(5–6):693–700
16. Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6(1):1–12
17. Davison Z, de Blacquiere GE, Westley BR, May FE (2011) Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 13(6):504–515
18. Rabe K, Lehrke M, Parhofer KG, Broedl UC (2008) Adipokines and insulin resistance. Mol Med 14(11–12):741–751
19. Haffner SM (1996) Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. Horm Res 45(3–5):233–237
20. Dowling RJ, Goodwin PJ, Stambolic V (2011) Understanding the benefit of metformin use in cancer treatment. BMC Med 9:33
21. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE et al (2009) Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8(13):2031–2040
22. Chen TW, Liang YN, Feng D, Tao LY, Qi K, Zhang HY et al (2013) Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90. J BUON 18(1):51–56
23. Vazquez-Martin A, Oliveras-Ferraros C, Del BS, Martin-Castillo B, Menendez JA (2011) The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 126(2):355–364
24. Ben SI, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P et al (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27(25):3576–3586
25. Noto H, Goto A, Tsujimoto T, Noda M (2012) Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 7(3):e33411
26. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A (2013) Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE 8(8):e71583
27. Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K et al (2014) Metformin does not affect cancer risk: a cohort study in the UK Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 37(9):2522–2532
28. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS (2013) Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 62(7):922–934
29. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM (2012) Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 97(7):E1170–E1175
30. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH (2012) The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res 2012:413782
31. Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie K (2013) Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab 15(4):349–357
32. Janghorbani M, Dehghani M, Salehi-Marzijarani M (2012) Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm Cancer 3(4):137–146
33. Mannucci E (2012) Insulin therapy and cancer in type 2 diabetes. ISRN Endocrinol 2012:240634
34. Staiger K, Hennige AM, Staiger H, Haring HU, Kellerer M (2007) Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 39(1):65–67
35. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH et al (2012) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 55(1):51–62
36. Habel LA, Danforth KN, Quesenberry CP, Capra A, Van Den Eeden SK, Weiss NS et al (2013) Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care 36:3953–3960
37. Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K et al (2012) Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 107(9):1608–1617